The recent clinical study update from Regeneron Pharmaceuticals and Sanofi focuses on the investigation of Itepekimab, an anti-IL-33 monoclonal antibody, to understand its effects ...

Adherence to medications can be an issue in all disease types, but it’s especially challenging in chronic obstructive pulmonary disease (COPD). While there are medications available to control ...

Recent advancements in COPD treatments are providing patients with potential new first-line treatments. Pharmaceutical ...

Patients with chronic obstructive pulmonary disease (COPD) often require complex medication regimens that are associated with significant disease severity, comorbidities, and multidimensional ...

And keep in mind that COPD treatment is a long-term journey with many facets, and each case is different. For example, you might be great at keeping up with your medications and doctor ...

A new COPD drug, developed by Verona Pharma, was approved by the FDA Wednesday. The drug, ensifentrine, is the first new type of maintenance treatment for COPD in over a decade.

Researchers have found a promising treatment breakthrough for chronic obstructive pulmonary disease (COPD) that avoids many ...

In the first half of 2024, many posts on X, formerly Twitter, from U.S. health care professionals discussing COPD therapies focused on ventilation support, medications and palliative care ...

People with schizophrenia are more likely to develop chronic obstructive pulmonary disease (COPD), suggesting a possible ...

A new COPD drug, developed by Verona Pharma, was approved by the FDA Wednesday. The drug, ensifentrine, is the first new type of maintenance treatment for COPD in over a decade. In clinical trials ...

Researchers have found a promising treatment breakthrough for Chronic Obstructive Pulmonary Disease (COPD) that avoids many ...

Pulmonology > COPD Certain Diabetes Medications May Ease COPD — Propensity-matched data support another benefit of two drug classes by Crystal Phend, Contributing Editor, MedPage Today February ...